QCG
RARE icon

Quadrant Capital Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Quadrant Capital Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-400
Closed -$9.2K – 2788
2025
Q4 		$9.2K Buy
400
+264
+194% +$8.68K ﹤0.01% 2229
2025
Q3 		$4.09K Buy
+136
New +$4.08K ﹤0.01% 2356
2025
Q2 		– Sell
-298
Closed -$10.8K – 2300
2025
Q1 		$10.8K Buy
298
+11
+4% +$458 ﹤0.01% 2206
2024
Q4 		$12.1K Hold
287
– – ﹤0.01% 2068
2024
Q3 		$15.9K Hold
287
– – ﹤0.01% 1984
2024
Q2 		$11.8K Sell
287
-110
-28% -$4.7K ﹤0.01% 2063
2024
Q1 		$18.5K Buy
397
+80
+25% +$3.77K ﹤0.01% 1880
2023
Q4 		$15.2K Sell
317
-94
-23% -$3.64K ﹤0.01% 1917
2023
Q3 		$14.7K Sell
411
-756
-65% -$30K ﹤0.01% 1839
2023
Q2 		$53.8K Sell
1,167
-163
-12% -$7.56K 0.01% 1223
2023
Q1 		$53.3K Buy
1,330
+406
+44% +$17.4K 0.01% 1203
2022
Q4 		$42.8K Buy
924
+487
+111% +$19.2K ﹤0.01% 1253
2022
Q3 		$18K Buy
437
+266
+156% +$13.7K ﹤0.01% 1615
2022
Q2 		$10K Buy
171
+149
+677% +$9.17K ﹤0.01% 1672
2022
Q1 		$1K Sell
22
-37
-63% -$2.57K ﹤0.01% 2365
2021
Q4 		$5K Buy
59
+34
+136% +$2.77K ﹤0.01% 1892
2021
Q3 		$2K Buy
25
+22
+733% +$1.99K ﹤0.01% 2183
2021
Q2 		$0 Sell
3
-54
-95% -$5.63K ﹤0.01% 2527
2021
Q1 		$6K Buy
+57
New +$7.76K ﹤0.01% 1736
2020
Q2 		– Sell
-4
Closed – – 2362
2020
Q1 		$0 Buy
+4
New +$208 ﹤0.01% 2237
2019
Q4 		– Sell
-136
Closed -$5K – 2475
2019
Q3 		$5K Buy
+136
New +$7.39K ﹤0.01% 1928
2016
Q2 		– Sell
-94
Closed -$5K – 2059
2016
Q1 		$5K Buy
94
+39
+71% +$2.55K ﹤0.01% 1171
2015
Q4 		$6K Buy
+55
New +$5.5K ﹤0.01% 1005

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Quadrant Capital Group's RARE Position: Q1 2026 in Review

Quadrant Capital Group sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 400 shares — an estimated $9.2K sold.

Quadrant Capital Group first reported a position in RARE in Q4 2015 and held it in 23 quarters. The position peaked at $53.8K in Q2 2023. 298 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Quadrant Capital Group reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 400 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $9.2K.
  • Quadrant Capital Group first reported a position in Ultragenyx Pharmaceutical in Q4 2015 and held it in 23 quarters.
  • Quadrant Capital Group's Ultragenyx Pharmaceutical position peaked at $53.8K in Q2 2023.
  • 298 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.